- call +1-201-465-4211
- email sales@mrinsights.biz
Dendritic cells (DCs) refer to rare kind of leukocytes. They have prompted their recent application to therapeutic cancer vaccinations as they are uniquely effective in their ability to present antigens to T cells.
Scope of the Report:
This report focuses on the Dendritic Cell Cancer Vaccine in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
The worldwide market for Dendritic Cell Cancer Vaccine is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from xx million US$ in 2017, according to a new GIR (Global Info Research) study.
Market Segment by Manufacturers, this report covers
Medigene
Activarti
Argos Therapeutics
Batavia Bioservices
Bellicum Pharmaceuticals
Creagene
DanDrit Biotech
DCPrime
Sanpower Corporation (Dendreon)
Elios Therapeutics
Immunicum
Kiromic
Merck
Northwest Biotherapeutics
Glaxo Smith Kline
ImmunoCellular
Tella
Vaxil Bio
Medigene
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
CreaVax
Sipuleucel-T (Provenge)
Others
Market Segment by Applications, can be divided into
Pediatrics
Adults
There are 15 Chapters to deeply display the global Dendritic Cell Cancer Vaccine market.
Chapter 1, to describe Dendritic Cell Cancer Vaccine Introduction, product scope, market overview, market opportunities, market risk, market driving force;
Chapter 2, to analyze the top manufacturers of Dendritic Cell Cancer Vaccine, with sales, revenue, and price of Dendritic Cell Cancer Vaccine, in 2016 and 2017;
Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;
Chapter 4, to show the global market by regions, with sales, revenue and market share of Dendritic Cell Cancer Vaccine, for each region, from 2013 to 2018;
Chapter 5, 6, 7, 8 and 9, to analyze the market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions;
Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2013 to 2018;
Chapter 12, Dendritic Cell Cancer Vaccine market forecast, by regions, type and application, with sales and revenue, from 2018 to 2023;
Chapter 13, 14 and 15, to describe Dendritic Cell Cancer Vaccine sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
Table of Contents
1 Market Overview
1.1 Dendritic Cell Cancer Vaccine Introduction
1.2 Market Analysis by Type
1.2.1 CreaVax
1.2.2 Sipuleucel-T (Provenge)
1.2.3 Others
1.3 Market Analysis by Applications
1.3.1 Pediatrics
1.3.2 Adults
1.4 Market Analysis by Regions
1.4.1 North America (United States, Canada and Mexico)
1.4.1.1 United States Market States and Outlook (2013-2023)
1.4.1.2 Canada Market States and Outlook (2013-2023)
1.4.1.3 Mexico Market States and Outlook (2013-2023)
1.4.2 Europe (Germany, France, UK, Russia and Italy)
1.4.2.1 Germany Market States and Outlook (2013-2023)
1.4.2.2 France Market States and Outlook (2013-2023)
1.4.2.3 UK Market States and Outlook (2013-2023)
1.4.2.4 Russia Market States and Outlook (2013-2023)
1.4.2.5 Italy Market States and Outlook (2013-2023)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
1.4.3.1 China Market States and Outlook (2013-2023)
1.4.3.2 Japan Market States and Outlook (2013-2023)
1.4.3.3 Korea Market States and Outlook (2013-2023)
1.4.3.4 India Market States and Outlook (2013-2023)
1.4.3.5 Southeast Asia Market States and Outlook (2013-2023)
1.4.4 South America, Middle East and Africa
1.4.4.1 Brazil Market States and Outlook (2013-2023)
1.4.4.2 Egypt Market States and Outlook (2013-2023)
1.4.4.3 Saudi Arabia Market States and Outlook (2013-2023)
1.4.4.4 South Africa Market States and Outlook (2013-2023)
1.4.4.5 Nigeria Market States and Outlook (2013-2023)
1.5 Market Dynamics
1.5.1 Market Opportunities
1.5.2 Market Risk
1.5.3 Market Driving Force
2 Manufacturers Profiles
2.1 Medigene
2.1.1 Business Overview
2.1.2 Dendritic Cell Cancer Vaccine Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 Medigene Dendritic Cell Cancer Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.2 Activarti
2.2.1 Business Overview
2.2.2 Dendritic Cell Cancer Vaccine Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 Activarti Dendritic Cell Cancer Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.3 Argos Therapeutics
2.3.1 Business Overview
2.3.2 Dendritic Cell Cancer Vaccine Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 Argos Therapeutics Dendritic Cell Cancer Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.4 Batavia Bioservices
2.4.1 Business Overview
2.4.2 Dendritic Cell Cancer Vaccine Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 Batavia Bioservices Dendritic Cell Cancer Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.5 Bellicum Pharmaceuticals
2.5.1 Business Overview
2.5.2 Dendritic Cell Cancer Vaccine Type and Applications
2.5.2.1 Product A
2.5.2.2 Product B
2.5.3 Bellicum Pharmaceuticals Dendritic Cell Cancer Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.6 Creagene
2.6.1 Business Overview
2.6.2 Dendritic Cell Cancer Vaccine Type and Applications
2.6.2.1 Product A
2.6.2.2 Product B
2.6.3 Creagene Dendritic Cell Cancer Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.7 DanDrit Biotech
2.7.1 Business Overview
2.7.2 Dendritic Cell Cancer Vaccine Type and Applications
2.7.2.1 Product A
2.7.2.2 Product B
2.7.3 DanDrit Biotech Dendritic Cell Cancer Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.8 DCPrime
2.8.1 Business Overview
2.8.2 Dendritic Cell Cancer Vaccine Type and Applications
2.8.2.1 Product A
2.8.2.2 Product B
2.8.3 DCPrime Dendritic Cell Cancer Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.9 Sanpower Corporation (Dendreon)
2.9.1 Business Overview
2.9.2 Dendritic Cell Cancer Vaccine Type and Applications
2.9.2.1 Product A
2.9.2.2 Product B
2.9.3 Sanpower Corporation (Dendreon) Dendritic Cell Cancer Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.10 Elios Therapeutics
2.10.1 Business Overview
2.10.2 Dendritic Cell Cancer Vaccine Type and Applications
2.10.2.1 Product A
2.10.2.2 Product B
2.10.3 Elios Therapeutics Dendritic Cell Cancer Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.11 Immunicum
2.11.1 Business Overview
2.11.2 Dendritic Cell Cancer Vaccine Type and Applications
2.11.2.1 Product A
2.11.2.2 Product B
2.11.3 Immunicum Dendritic Cell Cancer Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.12 Kiromic
2.12.1 Business Overview
2.12.2 Dendritic Cell Cancer Vaccine Type and Applications
2.12.2.1 Product A
2.12.2.2 Product B
2.12.3 Kiromic Dendritic Cell Cancer Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.13 Merck
2.13.1 Business Overview
2.13.2 Dendritic Cell Cancer Vaccine Type and Applications
2.13.2.1 Product A
2.13.2.2 Product B
2.13.3 Merck Dendritic Cell Cancer Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.14 Northwest Biotherapeutics
2.14.1 Business Overview
2.14.2 Dendritic Cell Cancer Vaccine Type and Applications
2.14.2.1 Product A
2.14.2.2 Product B
2.14.3 Northwest Biotherapeutics Dendritic Cell Cancer Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.15 Glaxo Smith Kline
2.15.1 Business Overview
2.15.2 Dendritic Cell Cancer Vaccine Type and Applications
2.15.2.1 Product A
2.15.2.2 Product B
2.15.3 Glaxo Smith Kline Dendritic Cell Cancer Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.16 ImmunoCellular
2.16.1 Business Overview
2.16.2 Dendritic Cell Cancer Vaccine Type and Applications
2.16.2.1 Product A
2.16.2.2 Product B
2.16.3 ImmunoCellular Dendritic Cell Cancer Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.17 Tella
2.17.1 Business Overview
2.17.2 Dendritic Cell Cancer Vaccine Type and Applications
2.17.2.1 Product A
2.17.2.2 Product B
2.17.3 Tella Dendritic Cell Cancer Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.18 Vaxil Bio
2.18.1 Business Overview
2.18.2 Dendritic Cell Cancer Vaccine Type and Applications
2.18.2.1 Product A
2.18.2.2 Product B
2.18.3 Vaxil Bio Dendritic Cell Cancer Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.19 Medigene
2.19.1 Business Overview
2.19.2 Dendritic Cell Cancer Vaccine Type and Applications
2.19.2.1 Product A
2.19.2.2 Product B
2.19.3 Medigene Dendritic Cell Cancer Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
3 Global Dendritic Cell Cancer Vaccine Sales, Revenue, Market Share and Competition by Manufacturer (2016-2017)
3.1 Global Dendritic Cell Cancer Vaccine Sales and Market Share by Manufacturer (2016-2017)
3.2 Global Dendritic Cell Cancer Vaccine Revenue and Market Share by Manufacturer (2016-2017)
3.3 Market Concentration Rate
3.3.1 Top 3 Dendritic Cell Cancer Vaccine Manufacturer Market Share in 2017
3.3.2 Top 6 Dendritic Cell Cancer Vaccine Manufacturer Market Share in 2017
3.4 Market Competition Trend
4 Global Dendritic Cell Cancer Vaccine Market Analysis by Regions
4.1 Global Dendritic Cell Cancer Vaccine Sales, Revenue and Market Share by Regions
4.1.1 Global Dendritic Cell Cancer Vaccine Sales and Market Share by Regions (2013-2018)
4.1.2 Global Dendritic Cell Cancer Vaccine Revenue and Market Share by Regions (2013-2018)
4.2 North America Dendritic Cell Cancer Vaccine Sales and Growth Rate (2013-2018)
4.3 Europe Dendritic Cell Cancer Vaccine Sales and Growth Rate (2013-2018)
4.4 Asia-Pacific Dendritic Cell Cancer Vaccine Sales and Growth Rate (2013-2018)
4.5 South America Dendritic Cell Cancer Vaccine Sales and Growth Rate (2013-2018)
4.6 Middle East and Africa Dendritic Cell Cancer Vaccine Sales and Growth Rate (2013-2018)
5 North America Dendritic Cell Cancer Vaccine by Countries
5.1 North America Dendritic Cell Cancer Vaccine Sales, Revenue and Market Share by Countries
5.1.1 North America Dendritic Cell Cancer Vaccine Sales and Market Share by Countries (2013-2018)
5.1.2 North America Dendritic Cell Cancer Vaccine Revenue and Market Share by Countries (2013-2018)
5.2 United States Dendritic Cell Cancer Vaccine Sales and Growth Rate (2013-2018)
5.3 Canada Dendritic Cell Cancer Vaccine Sales and Growth Rate (2013-2018)
5.4 Mexico Dendritic Cell Cancer Vaccine Sales and Growth Rate (2013-2018)
6 Europe Dendritic Cell Cancer Vaccine by Countries
6.1 Europe Dendritic Cell Cancer Vaccine Sales, Revenue and Market Share by Countries
6.1.1 Europe Dendritic Cell Cancer Vaccine Sales and Market Share by Countries (2013-2018)
6.1.2 Europe Dendritic Cell Cancer Vaccine Revenue and Market Share by Countries (2013-2018)
6.2 Germany Dendritic Cell Cancer Vaccine Sales and Growth Rate (2013-2018)
6.3 UK Dendritic Cell Cancer Vaccine Sales and Growth Rate (2013-2018)
6.4 France Dendritic Cell Cancer Vaccine Sales and Growth Rate (2013-2018)
6.5 Russia Dendritic Cell Cancer Vaccine Sales and Growth Rate (2013-2018)
6.6 Italy Dendritic Cell Cancer Vaccine Sales and Growth Rate (2013-2018)
7 Asia-Pacific Dendritic Cell Cancer Vaccine by Countries
7.1 Asia-Pacific Dendritic Cell Cancer Vaccine Sales, Revenue and Market Share by Countries
7.1.1 Asia-Pacific Dendritic Cell Cancer Vaccine Sales and Market Share by Countries (2013-2018)
7.1.2 Asia-Pacific Dendritic Cell Cancer Vaccine Revenue and Market Share by Countries (2013-2018)
7.2 China Dendritic Cell Cancer Vaccine Sales and Growth Rate (2013-2018)
7.3 Japan Dendritic Cell Cancer Vaccine Sales and Growth Rate (2013-2018)
7.4 Korea Dendritic Cell Cancer Vaccine Sales and Growth Rate (2013-2018)
7.5 India Dendritic Cell Cancer Vaccine Sales and Growth Rate (2013-2018)
7.6 Southeast Asia Dendritic Cell Cancer Vaccine Sales and Growth Rate (2013-2018)
8 South America Dendritic Cell Cancer Vaccine by Countries
8.1 South America Dendritic Cell Cancer Vaccine Sales, Revenue and Market Share by Countries
8.1.1 South America Dendritic Cell Cancer Vaccine Sales and Market Share by Countries (2013-2018)
8.1.2 South America Dendritic Cell Cancer Vaccine Revenue and Market Share by Countries (2013-2018)
8.2 Brazil Dendritic Cell Cancer Vaccine Sales and Growth Rate (2013-2018)
8.3 Argentina Dendritic Cell Cancer Vaccine Sales and Growth Rate (2013-2018)
8.4 Colombia Dendritic Cell Cancer Vaccine Sales and Growth Rate (2013-2018)
9 Middle East and Africa Dendritic Cell Cancer Vaccine by Countries
9.1 Middle East and Africa Dendritic Cell Cancer Vaccine Sales, Revenue and Market Share by Countries
9.1.1 Middle East and Africa Dendritic Cell Cancer Vaccine Sales and Market Share by Countries (2013-2018)
9.1.2 Middle East and Africa Dendritic Cell Cancer Vaccine Revenue and Market Share by Countries (2013-2018)
9.2 Saudi Arabia Dendritic Cell Cancer Vaccine Sales and Growth Rate (2013-2018)
9.3 UAE Dendritic Cell Cancer Vaccine Sales and Growth Rate (2013-2018)
9.4 Egypt Dendritic Cell Cancer Vaccine Sales and Growth Rate (2013-2018)
9.5 Nigeria Dendritic Cell Cancer Vaccine Sales and Growth Rate (2013-2018)
9.6 South Africa Dendritic Cell Cancer Vaccine Sales and Growth Rate (2013-2018)
10 Global Dendritic Cell Cancer Vaccine Market Segment by Type
10.1 Global Dendritic Cell Cancer Vaccine Sales, Revenue and Market Share by Type (2013-2018)
10.1.1 Global Dendritic Cell Cancer Vaccine Sales and Market Share by Type (2013-2018)
10.1.2 Global Dendritic Cell Cancer Vaccine Revenue and Market Share by Type (2013-2018)
10.2 CreaVax Sales Growth and Price
10.2.1 Global CreaVax Sales Growth (2013-2018)
10.2.2 Global CreaVax Price (2013-2018)
10.3 Sipuleucel-T (Provenge) Sales Growth and Price
10.3.1 Global Sipuleucel-T (Provenge) Sales Growth (2013-2018)
10.3.2 Global Sipuleucel-T (Provenge) Price (2013-2018)
10.4 Others Sales Growth and Price
10.4.1 Global Others Sales Growth (2013-2018)
10.4.2 Global Others Price (2013-2018)
11 Global Dendritic Cell Cancer Vaccine Market Segment by Application
11.1 Global Dendritic Cell Cancer Vaccine Sales Market Share by Application (2013-2018)
11.2 Pediatrics Sales Growth (2013-2018)
11.3 Adults Sales Growth (2013-2018)
12 Dendritic Cell Cancer Vaccine Market Forecast (2018-2023)
12.1 Global Dendritic Cell Cancer Vaccine Sales, Revenue and Growth Rate (2018-2023)
12.2 Dendritic Cell Cancer Vaccine Market Forecast by Regions (2018-2023)
12.2.1 North America Dendritic Cell Cancer Vaccine Market Forecast (2018-2023)
12.2.2 Europe Dendritic Cell Cancer Vaccine Market Forecast (2018-2023)
12.2.3 Asia-Pacific Dendritic Cell Cancer Vaccine Market Forecast (2018-2023)
12.2.4 South America Dendritic Cell Cancer Vaccine Market Forecast (2018-2023)
12.2.5 Middle East and Africa Dendritic Cell Cancer Vaccine Market Forecast (2018-2023)
12.3 Dendritic Cell Cancer Vaccine Market Forecast by Type (2018-2023)
12.3.1 Global Dendritic Cell Cancer Vaccine Sales Forecast by Type (2018-2023)
12.3.2 Global Dendritic Cell Cancer Vaccine Market Share Forecast by Type (2018-2023)
12.4 Dendritic Cell Cancer Vaccine Market Forecast by Application (2018-2023)
12.4.1 Global Dendritic Cell Cancer Vaccine Sales Forecast by Application (2018-2023)
12.4.2 Global Dendritic Cell Cancer Vaccine Market Share Forecast by Application (2018-2023)
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.1.3 Marketing Channel Future Trend
13.2 Distributors, Traders and Dealers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Data Source
List of Tables and Figures
Figure Dendritic Cell Cancer Vaccine Picture
Table Product Specifications of Dendritic Cell Cancer Vaccine
Figure Global Sales Market Share of Dendritic Cell Cancer Vaccine
ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems
Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system
Global Outreach6 Major regions and 40+ countries level analysis accomplished
Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery
